SEC Tracker
Get the app

Possible new Spyre Therapeutics shares

SYREDilution

Last raise Oct 6, 2026, 424B5: 4.1M shares (4.7% of the 88.2M then) at $85.00, $350M gross

Known so far: no new shares from the prospectus covers read · shelf not limited by the baby-shelf rule · not yet read: converts, ATM.

Shelf room

  • Room today not capped by the baby-shelf rule ($1.1B float, Jun 30, 2025)
How this is worked out

Shelf room on the S-3ASR of Jun 26, 2026: not limited by the baby-shelf rule, because the $1.1B public float stated as of Jun 30, 2025 is $75M or more. Sources: S-3ASR Jun 26, 2026, effective Jun 26, 2026 · public float, as of Jun 30, 2025.

What could become new Spyre Therapeutics (SYRE) shares: warrants and options and RSUs, each with the 10-Q, 10-K, S-3 or 424B filing it comes from.

Spyre Therapeutics dilution ladder

Every source of new shares on record, from the filings that created it.

95M outstanding; up to 105.2M fully diluted, +11%

  1. Outstandingas of Oct 27, 2026 (10-Q filed Nov 3) · share count on the cover page
    95M
  2. Warrants1.3M, at $22.4910-Q Nov 3, 2026 · securities left out of diluted EPS
    +1.3M
  3. Options and RSUs8.8M options, 150K RSUs10-Q Nov 3, 2026 · securities left out of diluted EPS
    +8.9M

Not stated in the filings we read: an ATM program, convertible notes.

Counts, sizes and prices as stated in each filing; the fully diluted count is arithmetic on them. Dollars become shares only at a price a filing states. Not advice.

Shares outstanding

95.0M

Feb 2025 to Oct 2026: from 60.3M to 95.0M.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.